← All trials
NCT06882096
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 28, 2025
- Primary completion
- Dec 31, 2026
- Completion date
- Jun 30, 2027
- First posted
- Mar 18, 2025
- Last posted
- May 6, 2025
- Enrollment
- 32
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Metro International Biotech, LLCLead sponsor
- Harvard UniversityOfficial
- Metro International Biotech, LLCSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.